Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Which patients with metastatic NSCLC with an EGFR mutation would you treat with chemotherapy & osimertinib or amivantamab & lazertinib, and how would you choose between the two regimens?
Related Questions
How would you treat a patient with newly diagnosed ALK+ Stage IIIB non-small cell lung cancer (NSCLC)?
Would you use combination of weekly low dose carboplatin and Taxol in patient with small cell lung cancer with poor performance status or cytopenia?
In light of recent retrospective data from France on EGFR TKIs use with PPIs showing negative outcomes in NSCLC patients would you consider discontinuing PPIs or changing PPIs to H2 inhibitors?
How would you approach post-chemoradiation consolidation in a patient with stage III lung adenocarcinoma with an EGFR exon 18 G719A mutation and highly positive PD-L1 level?
How would you approach local therapy (surgery or RT) in a patient with radiographic complete response after chemoimmunotherapy for non-small-cell lung cancer?
What are strategies to deal with grade 3/4 anorexia associated with Osimertinib?
How do you treat Stage IIIC T4N3 NSCLC?
In a patient with node-positive limited-stage small cell lung cancer, how do you approach radiation in a patient whose small primary tumor resolves after one cycle of chemotherapy?
What would be your approach in a patient who presented with a solitary brain metastasis that resolved after chemo without local therapy?
What is your approach for an RA patient with lung cancer who is starting immunotherapy?
